+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Global Situation of Growth Hormone Treatment in Growth Hormone- Deficient Children

      Hormone Research in Paediatrics

      S. Karger AG

      Regulatory system, Cost of GH, GH deficiency, Criteria of GH treatment, Diagnostic, Dose of GH

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Diagnostic criteria and treatment modalities were investigated through questionnaires from eleven countries and compared with those in Japan. All countries but Australia, where the patients can be treated with GH judged by only auxological data, use the combination of auxological data and peak GH value in provocation tests. GH value is still gold standard, but the cut off value differs among countries. Apart from the differences in cut off value, since it is well-known that GH concentrations vary according to the assay methods and measurement kits, standardization of the measurement kits is mandatory. GH dose ranges between 0.5 and 0.7 IU/kg/week in most countries. The lowest dose (fixed dose of 0.5 IU/kg/week) is used in Japan and the heightest dose (1.05 IU/kg/week) is used in the USA. The costs for GH treatment are most expensive in Japan.

          Related collections

          Most cited references 1

          • Record: found
          • Abstract: found
          • Article: not found

          Short stature and growth hormone therapy. A national study of physician recommendation patterns.

          To determine current expert opinion and recommendations regarding the controversial issue of the use of growth hormone (GH) to treat short children who do not have classical GH deficiency (non-GHD children).

            Author and article information

            Horm Res Paediatr
            Hormone Research in Paediatrics
            S. Karger AG
            November 1999
            17 November 2004
            : 51
            : Suppl 3
            : 75-80
            Department of Endocrinology and Metabolism, National Children’s Medical Research Center, Tokyo, Japan
            53166 Horm Res 1999;51(suppl 3):75–80
            © 1999 S. Karger AG, Basel

            Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

            Page count
            Tables: 4, References: 5, Pages: 6
            Meet-the-Professor Session


            Comment on this article